Pharmaceuticals

Revenue of the G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Predicted to Achieve $2.42 Billion by 2030, Driven by 32.9% CAGR

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market in 2026, and what figure is it projected to hit by 2030?

Recent years have witnessed remarkable growth in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market size. This market is projected to expand from $0.59 billion in 2025 to $0.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 32.7%. The expansion observed in past periods resulted from advancements in targeted cancer therapy research, a greater incidence of multiple myeloma cases, the expansion of monoclonal antibody development programs, enhancements in clinical trial infrastructure, and growing investments in oncology drug discovery.

The market for g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies is anticipated to experience substantial expansion over the coming years. Projections indicate this market will ascend to $2.42 billion by 2030, demonstrating a robust compound annual growth rate (CAGR) of 32.9%. The projected growth is primarily driven by several factors, including a rise in regulatory clearances for targeted biologics, increasing patient demand for individualized cancer treatments, the broadening of next-generation immunotherapy platforms, escalating investments in precision medicine ecosystems, and the wider uptake of biomarker-guided therapy choices. Key developments anticipated during this period encompass the accelerated creation of bispecific antibody therapies, a heightened emphasis on gprc5d biomarker-informed patient stratification, the expanding implementation of CAR-T cell platforms, the growth of clinical pipelines in precision oncology, and improved integration of companion diagnostics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33116&type=smp

Which Drivers Are Affecting Market Participation In The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

The increasing occurrence of myeloma is projected to fuel the expansion of the GPRC5D-targeted therapies market in the future. Myeloma, a malignancy originating in plasma cells within the bone marrow, interferes with the regular production of blood cells and has the potential to lead to bone injury, anemia, and renal issues. The growing frequency of myeloma is partly attributable to an aging populace, given that the likelihood of developing plasma cell disorders increases with advancing age as genetic alterations build up over years. GPRC5D-targeted therapies provide a treatment for myeloma by attaching to the GPRC5D protein found on cancerous plasma cells, subsequently guiding the immune system, particularly T cells, to specifically eliminate these malignant cells while largely preserving healthy cells. For example, in January 2026, the American Cancer Society, a professional organization located in the US, anticipates that in 2026, the United States will report about 36,000 new cases of multiple myeloma, consisting of 20,150 cases in men and 15,850 cases in women, alongside an expected 10,850 deaths, with 5,780 men and 5,070 women affected. Consequently, the expanding prevalence of myeloma is a key factor propelling the growth of the GPRC5D-targeted therapies market.

What Segment Categories Are Covered In The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types

2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications

3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems

4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration

5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users

Subsegments:

1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies

2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies

3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies

4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics

What Trends Are Driving The Growth Trajectory Of The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market?

Leading firms in the GPRC5D targeted therapies sector are concentrating on creating novel solutions, like bispecific T cell engagers, to boost the immune system’s ability to target cancer cells and increase the effectiveness of treatments. A bispecific T-cell engager (BiTE) is a specific kind of immunotherapy molecule engineered to link T-cells straight to cancer cells through simultaneous binding, thereby prompting the T-cells to eradicate the specific cancer cells. As an illustration, in August 2023, the US-based healthcare corporation Johnson & Johnson secured approval from the European Commission for TALVEY (talquetamab), which is Janssen’s bispecific antibody therapy designed to target GPRC5D, intended for patients with relapsed and refractory multiple myeloma (RRMM) who have undergone a minimum of three previous therapies. This particular therapy stands as a pioneering bispecific T-cell engager, targeting GPRC5D on multiple myeloma cells and CD3 on T cells, aimed at addressing relapsed/refractory multiple myeloma in patients who have received extensive prior treatments. Its primary objective is to deliver lasting responses (ORR >70% in trials) following a minimum of four prior therapies, offering benefits such as subcutaneous administration, prolonged improvements in quality of life, and continued effectiveness even after bispecifics or CAR-T treatments, thereby addressing a significant unmet requirement in advanced-stage disease.

Which Leading Companies Dominate The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Share?

Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptor-family-c-group-5-member-d-gprc5d-targeted-therapies-market-report

How Does The G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Perform Across Major Global Regions?

North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33116&type=smp

Browse Through More Reports Similar to the Global G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market 2026, By The Business Research Company

G Protein Coupled Receptors Market Report 2026

https://www.thebusinessresearchcompany.com/report/g-protein-coupled-receptors-global-market-report

Cc Chemokine Receptor Type 5 Market Report 2026

https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report

Gmp Cell Therapy Consumables Market Report 2026

https://www.thebusinessresearchcompany.com/report/gmp-cell-therapy-consumables-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info